

Study Delivery Q4 2017/18

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name Of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed To Recruit Target Number Of Patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
14/YH/1269	140294	A Phase 3, OpenLabel, Randomised, Parallel, 2Arm, MultiCenter Study of BMN 673 versus Physician's Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More than 2 Prior Chemotherapy Reg	Range Agreed	1	2	Not Available / Not Agreed			20/04/2017	2	Recruitment Finished
14/YH/0088	151005	Phase I study of KHK2823 in Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome	Range Agreed	4	8	Date Agreed	01/02/2017	4	30/06/2017	4	Recruitment Finished
15/NW/0543	181870	A Multicentre, Randomised, Doubleblind, Placebo controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus	Range Agreed	2	3	Date Agreed	30/04/2017	0	30/06/2017	0	Recruitment Finished
15/YH/0478	186697	A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Saefty and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis	Range Agreed	5	10	Date Agreed	31/10/2016	0	18/08/2017	0	Withdrawn By Host
16/EM/0386	211113	A 12-week double-blind, randomized, multicenter study comparing the efficacy and safety of once monthly subcutaneous 140 mg AMG 334 against placebo in adult episodic migAraine patients who have failed 2-4 prophylactic treatments	Number Agreed	4	4	Date Agreed	22/08/2016	2	03/05/2017	2	Recruitment Finished
16/EE/0463	214371	CLEE011A2404. Ribociclib and Letrozole in HR+, HER- breast cancer	Range Agreed	5	7	Date Agreed	31/12/2019	7	27/09/2017	7	Recruitment Finished
16/LO/2128	216431	Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes in Patients with Locally Advanced or Metastatic NSCLC	Number Agreed	10	40	Date Agreed	28/02/2019	2	08/11/2017	2	Withdrawn By Sponsor
16/LO/1854	184654	A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are	Range Agreed	50	100	Date Agreed	30/09/2017	57	18/05/2017	57	Recruitment Finished
16/SC/0521	202868	Estimating the burden of illness in adult atopc dermatitis patients	Number Agreed	6	6	Date Agreed	22/09/2017	8	18/09/2017	8	Recruitment Finished
16/LO/157	212991	A post-market registry of the BioMatrix Alpha TM (Cobalt Chromium Biolimus A9TM (BA9TM) drug-eluting	Range Agreed	20	50	Date Agreed	31/07/2017	44	26/10/2017	44	Recruitment Finished
15/NW/0261	165083	Safety and Performance Registry for an all-comers patient population with the Limus Elutin Orsiro Stent System within daily clinical practice - III (UK and Ireland Satellite)	Range Agreed	80	100	Date Agreed	31/10/2016	93	01/12/2017	200	Recruitment Finished
17/YH/0076	208944	CALM- DIEM – Controlling and Lowering Blood Pressure with the MobiusHD™ - Defining Efficacy Markers	Number Agreed	5	5	Date Agreed	31/08/2018	2	20/03/2018	2	Recruitment Finished